Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment

被引：0

作者：

Corassa, Marcelo ^{[1
]}

Abreu, Rodrigo Fonseca ^{[2
]}

Cordeiro de Lima, Vladmir Claudio ^{[1
]}

Torrezan, Giovana Tardim ^{[3
,4
]}

Cavalher, Felicia Peterson ^{[1
]}

Silva, Tullio Novaes ^{[2
]}

de Oliveira, Thiago Bueno ^{[1
]}

Freitas, Helano Carioca ^{[1
]}

Carraro, Dirce Maria ^{[3
,4
]}

Costa, Felipe D'Almeida ^{[2
]}

机构：

[1] AC Camargo Canc Ctr, Dept Med Oncol, R Prof Antonio Prudente, Sao Paulo, Brazil

[2] Dept Pathol, R Prof Antonio Prudente, Sao Paulo, Brazil

[3] AC Camargo Canc Ctr, Genom & Mol Biol Grp, Int Res Center CIPE, Sao Paulo, Brazil

[4] Natl Inst Sci & Technol Oncogen INCITO, Sao Paulo, Brazil

来源：

JCO PRECISION ONCOLOGY | 2022年 / 6卷

关键词：

SQUAMOUS-CELL CARCINOMA; HISTOLOGIC TRANSFORMATION; KINASE INHIBITORS; FREQUENCY; CANCER;

D O I：

10.1200/PO.22.00367

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：6

共 50 条

[41] Mechanisms of resistance for osimertinib for patients with EGFR-mutant lung cancer: MD Anderson Cancer Center single institution experience with osimertinib resistance
Le, Xiuning
Negrao, Marcelo Vailati
Nilsson, Monique
Robichaux, Jacqulyne
Roarty, Emily
Rinsurongkawong, Waree
Glisson, Bonnie
Zhang, Jianjun
Heymach, John V.
CANCER RESEARCH, 2018, 78 (13)
[42] Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
Sally J. Adua
Anna Arnal-Estapé
Minghui Zhao
Bowen Qi
Zongzhi Z. Liu
Carolyn Kravitz
Heather Hulme
Nicole Strittmatter
Francesc López-Giráldez
Sampada Chande
Alexandra E. Albert
Mary-Ann Melnick
Bomiao Hu
Katerina Politi
Veronica Chiang
Nicola Colclough
Richard J. A. Goodwin
Darren Cross
Paul Smith
Don X. Nguyen
Nature Communications, 13
[43] Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
Uchibori, Ken
Inase, Naohiko
Nishio, Makoto
Fujita, Naoya
Katayama, Ryohei
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 915 - 925
[44] Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
Oztan, A.
Fischer, S.
Schrock, A. B.
Erlich, R. L.
Lovly, C. M.
Stephens, P. J.
Ross, J. S.
Miller, V.
Ali, S. M.
Ou, S. -H. I.
Raez, L. E.
LUNG CANCER, 2017, 111 : 84 - 87
[45] Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report
Lee, Po-Hsin
Chang, Gee-Chen
CLINICAL LUNG CANCER, 2021, 22 (04) : E536 - E541
[46] Acquired an EGFR Amplification in EGFR Exon 20 insertion Lung Adenocarcinoma Resistant to First Line Osimertinib Treatment
Zhou, C.
Chen, Z.
Li, C.
Wang, H.
Lou, F.
Cao, S.
Liu, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S595 - S595
[47] Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma
Ahn, June Hong
THORACIC CANCER, 2020, 11 (09) : 2713 - 2716
[48] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
Smit, E.
Felip, E.
Karachaliou, N.
Ellers-Lenz, B.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
[49] Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models of EGFR-mutant cancer
Westover, David
Meador, Catherine B.
Ichihara, Eiki
Byrd, Hayden F.
Eberlein, Cath
Yan, Yingjun
Cross, Darren A.
Lovly, Christine M.
CANCER RESEARCH, 2017, 77
[50] MERTK activation drives osimertinib resistance in EGFR-mutant non small cell lung cancer
Yan, Dan
Huelse, Justus M.
Kireev, Dmitri
Tan, Zikang
Chen, Luxiao
Goyal, Subir
Wang, Xiaodong
Frye, Stephen, V
Behera, Madhusmita
Schneider, Frank
Ramalingam, Suresh S.
Owonikoko, Taofeek
Earp, H. Shelton
DeRyckere, Deborah
Graham, Douglas K.
JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (15):

← 1 2 3 4 5 →